IVIG + rituximab

This desensitization protocol, developed at Cedars-Sinai Medical Center, combines intravenous immunoglobulin (IVIG) and rituximab to manage highly HLA-sensitized patients awaiting kidney transplantation. Rituximab is a chimeric monoclonal antibody targeting the CD20 antigen on B cells, leading to their depletion and a reduction in the production of new anti-HLA antibodies. IVIG, a pooled human plasma product, provides immediate immunomodulation by neutralizing circulating antibodies, inhibiting complement-mediated injury, and modulating Fc receptor signaling. Together, these agents lower the levels of donor-specific antibodies (DSAs), enabling successful transplantation in patients who would otherwise face high risks of hyperacute or antibody-mediated rejection.

Other names

IVIG + rituximab-Cedars-Sinai Medical Center-kidney transplantationCedars-Sinai desensitization protocolJordan protocolIVIG and Rituximab for Desensitization